Composition for relieving visual fatigue containing lutein and bilberry extract and preparation method thereof

Abstract

The invention discloses a visual fatigue relieving composition containing lutein and bilberry extract and a preparation method thereof, and specifically belongs to the field of functional foods; the composition comprises components: a plant extract synergistic component, lutein and zinc gluconate; the plant extract synergistic component consists of bilberry extract, chrysanthemum extract, peanut skin extract and mulberry extract; the visual fatigue relieving composition provided by the invention can effectively relieve visual fatigue and significantly improve the visual fatigue condition; at the same time, the plant extract synergistic component has an obvious gain effect on the efficacy of the overall formula, and the plant extract synergistic component plays a key role in relieving visual fatigue; the visual fatigue relieving composition provided by the invention can improve the visual persistence of visual fatigue subjects and has a significant therapeutic effect.

Description

Technical Field

[0001] The invention belongs to the field of functional foods, and in particular relates to a composition for alleviating visual fatigue containing lutein and bilberry extract and a preparation method thereof. Background Art

[0002] With the development of society, computers, mobile phones and other tools have become indispensable tools in people's lives and offices. Long-term viewing of computers and mobile phones as well as the impact of physical and mental stress have led to excessive use of eyes, and visual fatigue is becoming more and more common.

[0003] Lutein is a carotenoid widely found in fruits, vegetables and other plants. It is the main pigment in the macular area of ​​the human retina. Humans cannot synthesize lutein on their own and can only rely on ingestion from external food. Lutein has strong antioxidant activity and can effectively prevent oxidation reactions, prevent and treat cataracts and macular degeneration. Its absorption spectrum contains near-blue-violet light, which can help the retina of the eye resist ultraviolet rays and prevent retinal pigment epithelial cells from being damaged by blue light.

[0004] Bilberry is a plant of the Ericaceae family and the genus Vaccinium. Mature bilberry is rich in anthocyanins, which have antioxidant and vision-improving effects. Studies have found that bilberry anthocyanins can effectively scavenge free radicals, eliminate the oxidative damage of ultraviolet rays to retinal cells, reduce blue light-induced damage to retinal photoreceptor cells, and prevent cataract formation, macular degeneration and glaucoma.

[0005] Chrysanthemum extract is a traditional Chinese medicine that has the effects of dispelling wind-heat, clearing the liver and improving eyesight. Modern research shows that chrysanthemum extract is rich in flavonoids, which can inhibit inflammatory responses and relieve eye discomfort. At the same time, chrysanthemum extract can also promote tear secretion and relieve dry eye symptoms.

[0006] Mulberry extract is a natural product rich in various nutrients, including vitamins, minerals, amino acids, etc. These nutrients can nourish eye tissues and promote the metabolism of eye cells, thereby improving eye health. At the same time, mulberry extract also has antioxidant and anti-inflammatory effects, which can reduce oxidative damage and inflammatory reactions in eye tissues.

[0007] However, although these extracts have the effects of relieving visual fatigue and protecting eye health, the effect of a single ingredient is often limited. Therefore, a variety of extracts with eye protection effects are scientifically proportioned and prepared into a composite, which can play a synergistic role and improve the effect of relieving visual fatigue. Summary of the invention

[0008] In view of the deficiencies in the prior art, the object of the present invention is to provide a composition and a functional food thereof that can relieve visual fatigue, comprising a plurality of extracts with eye-protecting effects such as lutein, bilberry extract, chrysanthemum extract, peanut skin extract and mulberry extract, and by scientifically proportioning and adopting an appropriate preparation process.

[0009] To achieve the above object, the present invention discloses the following technical solutions:

[0010] In a first aspect, the present invention provides a composition for relieving visual fatigue, wherein the composition comprises the following components in parts by mass:

[0011] 5-10 parts of plant extract synergistic components;

[0012] Lutein 0.01-0.02 parts;

[0013] Zinc gluconate 0.01-0.02 parts;

[0014] The plant extract synergistic component consists of bilberry extract, chrysanthemum extract, peanut skin extract and mulberry extract.

[0015] Preferably, the mass ratio of the bilberry extract, the chrysanthemum extract, the peanut skin extract and the mulberry extract is (2.5-3.5): (1.2-1.7): (0.1-0.4): (1.8-2.6).

[0016] Further preferably, the method for preparing the peanut skin extract comprises the following steps:

[0017] S1, drying, crushing and sieving the peanut skins to obtain peanut skin powder;

[0018] S2. The peanut skin powder obtained in step S1 is placed in a supercritical CO2 extraction kettle for extraction to obtain a peanut skin extract.

[0019] More preferably, in step S1, the peanut skins are dried at 60° C. for 4 hours and then crushed. After crushing, the peanut skins are sieved through a 120-mesh sieve to obtain peanut skin powder.

[0020] Further preferably, the supercritical CO2 extraction conditions in step S2 are: using ethanol with a concentration of 75 v / v% as the entrainer, the mass volume ratio of peanut skin powder to the entrainer is 1:2 g / mL, the entrainer flow acceleration is 0.5 L / h, the extraction temperature is 40°C, the extraction pressure is 10 MPa, the CO2 flow rate is 20 L / h, the separation pressure is 4 MPa, the separation temperature is 30°C, and the extraction time is 2 h.

[0021] Preferably, the composition further comprises excipients acceptable to functional foods or medicines.

[0022] In a second aspect, the present invention provides the use of the above-mentioned composition for relieving visual fatigue in the preparation of functional food with the effect of relieving visual fatigue.

[0023] In a third aspect, the present invention provides a lozenge for relieving visual fatigue, wherein the lozenge comprises the composition for relieving visual fatigue described in the first aspect, maltodextrin, magnesium stearate, silicon dioxide, microcrystalline cellulose, and a flavoring agent.

[0024] Preferably, the lozenge comprises the following components by mass percentage:

[0025] Plant extract synergistic components 5-10%;

[0026] Lutein 0.01-0.02%;

[0027] Zinc gluconate 0.01-0.02%;

[0028] Magnesium stearate 0.5-1%;

[0029] Silicon dioxide 0.1-0.2%;

[0030] Microcrystalline cellulose 15-20%;

[0031] Flavoring agent 0.001-0.002%;

[0032] Maltodextrin is added to 100%.

[0033] In a fourth aspect, the present invention provides a method for preparing the lozenge for relieving visual fatigue according to the third aspect, comprising the following preparation steps:

[0034] A1. Mix the components of the plant extract synergistic component according to the mass ratio, and then perform ultrafine grinding for 30 minutes, and pass through a 120-mesh sieve to obtain ultrafine powder of the plant extract synergistic component;

[0035] A2, maltodextrin and microcrystalline cellulose were subjected to ultrafine grinding for 30 min, and then maltodextrin was passed through a 120-mesh sieve and microcrystalline cellulose was passed through a 200-mesh sieve to obtain ultrafine maltodextrin powder and ultrafine microcrystalline cellulose powder;

[0036] A3. Mix lutein, zinc gluconate and silicon dioxide to obtain mixed powder A, mix the superfine powder of plant synergistic component and the superfine powder of maltodextrin evenly, add superfine powder of microcrystalline cellulose to mix to obtain mixed powder B, then place the mixed powder A, mixed powder B, magnesium stearate and flavoring agent in a mixing device and mix for 15-30 minutes to obtain a total mixed powder, and finally tablet the total mixed powder to obtain the lozenge for relieving visual fatigue.

[0037] In the present invention:

[0038] Bilberry extract is rich in anthocyanins, anthocyanins and other antioxidant active substances, which can improve the antioxidant capacity of the retina, strengthen the elasticity of the eye's microvessels, promote blood circulation, maintain normal eye pressure, ensure the nutrition supply of the eyes, and play a supporting role in visual fatigue and night vision.

[0039] The rich chemical components in chrysanthemum extract, such as flavonoids, volatile oils, organic acids, amino acids and trace elements, work together to relieve visual fatigue. The antioxidant properties of flavonoids help neutralize free radicals and reduce oxidative stress damage to the eyes. Organic acids can also protect the eyes from free radical damage; amino acids and trace elements provide essential nutrients for the eyes and support eye health. The combined effects of these ingredients help improve blood circulation, promote the supply of nutrients and the elimination of metabolic waste, thereby relieving visual fatigue caused by prolonged eye use.

[0040] Polyphenols in peanut skin extract, such as proanthocyanidins and flavonoids, have strong antioxidant properties. They can neutralize free radicals, reduce oxidative stress damage to the eyes, protect eye cells, and thus help relieve visual fatigue.

[0041] Mulberry extracts are rich in active ingredients, such as anthocyanins, flavonoids, phenolic acid compounds, polysaccharides, resveratrol and lutein, which work together to promote eye health. The antioxidant properties of anthocyanins and flavonoids help neutralize free radicals and reduce oxidative stress damage to the eye, while phenolic acid compounds also protect eye cells through antioxidant effects. Polysaccharides help maintain eye health by regulating immunity and anti-inflammatory effects. The anti-inflammatory and antioxidant effects of resveratrol, as well as the protective effect of lutein on the retina, have a positive effect on relieving visual fatigue.

[0042] The present invention finds that bilberry extract, chrysanthemum extract, peanut skin extract and mulberry extract have a mutually reinforcing effect on relieving visual fatigue. Visual fatigue is usually caused by cell apoptosis caused by decreased retinal function or stress response and inflammatory response, especially long-term use of the eyes leads to excessive accumulation of metabolic waste in the eyes and cannot be removed, causing various stress injuries. Bilberry extract, chrysanthemum extract, peanut skin extract and mulberry extract work together to relieve visual fatigue through various mechanisms such as anti-oxidation, anti-inflammation, and improvement of blood circulation through their rich antioxidant active ingredients.

[0043] Beneficial effects of the present invention:

[0044] 1. The lozenge for relieving visual fatigue provided by the present invention can effectively relieve visual fatigue and significantly improve the visual fatigue condition. The plant extract synergistic component provided by the present invention has a significant benefit effect on the efficacy of the overall formula, and the plant extract synergistic component plays a key role in relieving visual fatigue;

[0045] 2. The lozenges for relieving visual fatigue provided by the present invention can improve the visual persistence of subjects with visual fatigue, and the therapeutic effect is significant. After 60 days of trial consumption, the average visual persistence before and after the trial consumption is greatly improved by more than 10%. DETAILED DESCRIPTION

[0046] In order to make the purpose, technical scheme and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with specific embodiments. However, the following embodiments are only preferred embodiments of the present invention, not all. For the sake of clarity, all features of the actual embodiments are not described.

[0047] Based on the embodiments in the implementation manner, other embodiments obtained by those skilled in the art without making any creative work shall all fall within the protection scope of the present invention.

[0048] In the present invention:

[0049] Bilberry extract: purchased from Longlin Bioresource Co., Ltd.;

[0050] Chrysanthemum extract: purchased from Baichuan Kangze Biotechnology Co., Ltd.;

[0051] Mulberry extract: purchased from Hebei Hongtao Bioengineering Co., Ltd.;

[0052] Peanut skins: purchased from Qingdao Fudelong Food Co., Ltd.

[0053] Other raw materials are commercially available.

[0054] Preparation of peanut skin extract:

[0055] Step (1), pre-treating the peanut skins, drying the peanut skins in an oven at 60° C. for 4 hours, and then crushing them using a universal high-speed crusher, and passing through a 120-mesh sieve after crushing to obtain peanut skin powder;

[0056] Step (2), placing the dried peanut skin powder in a supercritical CO2 extraction kettle for extraction, the extraction conditions are: using 75v / v% ethanol as the entrainer, the mass volume ratio of peanut skin powder to the entrainer is 1:2 g / mL, the entrainer flow acceleration is 0.5L / h, the extraction temperature is 40°C, the extraction pressure is 10 MPa, the CO2 flow rate is 20 L / h, the separation pressure is 4 MPa, the separation temperature is 30°C, and the extraction time is 2 h, and finally the peanut skin extract is extracted.

[0057] Preparation of plant extract synergistic components:

[0058] The raw material components are compounded and mixed according to the dosage ratio in Table 1 to obtain the plant extract synergistic component.

[0059] Table 1 The mass ratio of each component of plant extract synergistic components

[0060] Plant extract synergistic component ① Plant extract synergistic component ② Plant extract synergistic component ③ Plant extract synergistic component ④ Bilberry Extract 2.5 3 3 3.5 Chrysanthemum Extract 1.2 1.5 1.5 1.7 Peanut Skin Extract 0.1 0.2 0.3 0.4 Mulberry Extract 1.8 2.0 2.4 2.6

[0061] Preparation of lozenges for relieving visual fatigue:

[0062] Step (1), weighing the raw material components of the plant extract synergistic component according to the ratio, and compounding and mixing, and then superfine grinding for 30 minutes, passing through a 120-mesh sieve, to obtain the processed plant extract synergistic component superfine powder for standby use;

[0063] Step (2), superfine grinding maltodextrin and microcrystalline cellulose for 30 minutes, then passing maltodextrin through a 120-mesh sieve and microcrystalline cellulose through a 200-mesh sieve to obtain superfine maltodextrin powder and superfine microcrystalline cellulose powder for later use;

[0064] Step (3), mixing lutein, zinc gluconate and silicon dioxide to obtain mixed powder A, mixing the superfine powder of the plant synergistic component and the superfine powder of maltodextrin evenly, adding the superfine powder of microcrystalline cellulose to mix to obtain mixed powder B, and then placing the mixed powder A, the mixed powder B, magnesium stearate and the flavoring agent in a mixing device and mixing for 15-30 minutes to obtain a total mixed powder;

[0065] Step (4), tabletting the total mixed powder to obtain the visual fatigue relieving lozenges of Examples 1-6, Comparative Examples 1-8 and a control group.

[0066] Table 2 Mass percentage of raw materials in Examples 1-6 (%)

[0067]

[0068] Table 3 Comparative Examples 1-8 Raw Materials Mass Percentage (%)

[0069]

[0070] Note: “-” in the table means not added.

[0071] Acute toxicity test

[0072] Experimental standard: The experiment was conducted in accordance with the method specified in GB 15193.3-2014 “National Food Safety Standard Acute Oral Toxicity Test”.

[0073] Animal grouping: 300 SPF SD rats, half male and half female, were divided into groups, and the individual weight values ​​of the same sex were within the range of the mean ± 20%.

[0074] Experimental method: Weigh the above-prepared Examples 1-6, Comparative Examples 1-8 and the control group as the test substance and prepare a 0.25g / mL test solution with deionized water. Before the test, the animals were fasted overnight (about 16h) and had free access to water. During the formal test, the test group animals were gavaged with the test solution at 20mL / kg body weight, and the test solution was gavaged twice within 24h, with an interval of about 4h between the two gavages. A small amount of feed was given during the period, and the first administration of the test substance was followed by fasting for about 3h. After the test substance was administered, the appearance and disappearance time of the signs of poisoning and the time of death were observed and recorded, and the observation period was 14 days. During the observation period, animals that died of poisoning should be grossly dissected and observed with the naked eye. If abnormalities in tissues or organs were found, further histopathological examinations were performed. Weigh them on days 0, 1, 3, 7, and 14, respectively.

[0075] Experimental results: The animals showed no abnormal symptoms during the administration of the test solution and the 14-day observation period, their weight increased normally, no animal died, and the LD50 was greater than 5g / kg body weight. At the end of the experiment, all animals were dissected and no abnormalities were found by naked eye observation.

[0076] Experimental conclusion: The test solution was tested according to GB 15193.3-2014 "National Food Safety Standard Acute Oral Toxicity Test", and the acute oral toxicity LD50 for SD rats was > 5g / kg body weight, which is actually non-toxic.

[0077] Functional evaluation of relieving visual fatigue

[0078] Purpose:

[0079] The visual fatigue relieving effect of the visual fatigue relieving lozenge of the present invention is evaluated by closely observing the visual improvement of the subjects before and after taking the visual fatigue relieving lozenge of the present invention through human food trial test.

[0080] Criteria for selecting subjects:

[0081] The subjects should be selected in accordance with the "Health Food Function Test and Evaluation Methods (2023 Edition)", including children, teenagers and adults who use their eyes for a long time and are prone to visual fatigue. However, subjects with allergic diseases of the eyes, infectious diseases of the eyes, fundus diseases with complications of the heart, brain, liver, and kidneys, and subjects who have taken short- or long-term drugs to improve visual fatigue or treat eye diseases should be excluded.

[0082] Observation items:

[0083] In order to ensure the safety of the subjects, routine blood and urine tests are performed on the subjects regularly. Adolescents and adults are also required to observe liver and kidney function, electrocardiogram, and chest X-ray examinations. Before and after the test, the subjects' eye pain, eye swelling, photophobia, blurred vision, dry eyes, foreign body sensation, tearing, the degree of general discomfort and the duration of clear vision are observed and recorded.

[0084] Table 4 Method for determining visual fatigue

[0085] Symptoms\Points 0 points 1 point 2 points 3 points Eye swelling none Occasional eye swelling Sometimes eye swelling, which gets better after rest Frequent eye swelling, improved after rest Eye pain none Occasional eye pain Sometimes eye pain Frequent eye pain photophobia none Occasionally photophobia Sometimes photophobia Often afraid of light Blurred vision none Occasionally blurry Sometimes blurred vision, relieved by rest Frequent blurriness, improves after rest Dry eyes none Occasionally dry Sometimes dryness Frequent dryness Foreign body sensation none Occasionally a foreign body sensation Sometimes there is a foreign body sensation Frequent foreign body sensation Tears none Occasionally tears Sometimes tears Frequent tears General discomfort related to vision none Occasionally feel sick Sometimes you feel sick Frequent general discomfort

[0086] Note: “Occasionally” means the condition occurs 1-2 times every 2 days; “Sometimes” means the condition occurs 1-3 times a day; “Frequently” means the condition occurs more than 3 times a day.

[0087] Statistical treatment:

[0088] Collect data before and after the experiment and use t test and X 2 SPSS 17.0 data processing software was used for the test. If P < 0.05 or P < 0.01, the difference was statistically significant.

[0089] Grouping:

[0090] 450 subjects aged 21-42 years old who are prone to visual fatigue due to long-term eye use were selected and randomly divided into a control group, embodiments 1-6 and comparative examples 1-8 according to vision examination results, symptoms and gender factors, a total of 15 groups, each with 30 people.

[0091] in,

[0092] Example group: taking the lozenges prepared in corresponding tasting examples 1-6, 0.4 g per lozenge, 1 lozenge each time, once a day;

[0093] Comparative Example Group: Take the lozenges prepared in Comparative Examples 1-8, 0.4 g per lozenge, 1 lozenge each time, once a day;

[0094] Control group: lozenges corresponding to the test control group, 0.4 g per tablet, 1 tablet each time, once a day.

[0095] After 60 days, the vision of the 15 groups of subjects was observed and recorded.

[0096] Judging criteria:

[0097] ① Ophthalmological symptoms: Eye pain, eye swelling, photophobia, blurred vision, dry eyes, foreign body sensation, tearing, and general discomfort. If 3 of the 8 symptoms are improved and other symptoms do not worsen, the symptom improvement is considered effective. If it does not meet the effective standard, it is considered ineffective. Symptom improvement efficiency (%) = number of symptom improvement cases / number of trial cases × 100.

[0098] ② Persistence of clear vision: According to the persistence of clear vision test method of "Health Food Function Test and Evaluation Method (2023 Edition)", if the average persistence of clear vision of the subjects is greater than or equal to 10% compared with before the test, it is judged to have the effect of relieving visual fatigue.

[0099] Test results:

[0100] Through close observation, after the subjects took various groups of drugs to relieve visual fatigue, the ophthalmic symptoms of eye pain, eye swelling, photophobia, blurred vision, dry eyes, foreign body sensation, tearing, and general discomfort were improved to varying degrees.

[0101] Table 5 Impact of visual fatigue symptoms

[0102] Group Number of cases efficient invalid Effectiveness (%) Control group 30 5 25 16.67% Example 1 30 22 8 73.33%** Example 2 30 21 9 70.00%** Example 3 30 21 9 70.00%** Example 4 30 20 10 66.67%** Example 5 30 18 12 60.00%** Example 6 30 16 14 53.33%** Comparative Example 1 30 12 18 40.00%# Comparative Example 2 30 10 20 33.33%# Comparative Example 3 30 11 19 36.67%# Comparative Example 4 30 11 19 36.67%# Comparative Example 5 30 9 21 30.00%# Comparative Example 6 30 9 21 30.00%# Comparative Example 7 30 10 20 33.33%# Comparative Example 8 30 8 22 26.67%#

[0103] Note: * indicates that the difference between the embodiment group and the control group is significant (P < 0.05), ** indicates that the difference is extremely significant (P < 0.01); # indicates that the difference between the comparative example group and the embodiment 3 group is significant (P < 0.05), ## indicates that the difference is extremely significant (P < 0.01).

[0104] Table 5 shows that after the subjects in Example 1-6 groups tried the lozenges for relieving visual fatigue provided by the present invention, the visual fatigue conditions were correspondingly improved. Among them, compared with the control group, the improvement rate of the visual fatigue conditions in Example 1-6 was more obvious (P<0.01), and the therapeutic effect was better, indicating that the plant extract synergistic component provided by the present invention has a significant enhancing effect on the efficacy of the overall formula, and the plant extract synergistic component plays a key role in relieving visual fatigue; compared with Comparative Examples 1-8, the improvement rate of the visual fatigue conditions in Example 3 was significantly better than that in Comparative Examples 1-8, indicating that the lack of any one of the components in the plant extract synergistic component provided by the present invention will have an adverse effect on the performance of the overall formula.

[0105] Table 6 Effect of visual persistence (n=30) ( , %)

[0106] Group Number of cases Before tasting (%) After tasting (%) Improvement value (%) Control group 30 57.3±3.1 65.1±3.4 7.8±2.6 Example 1 30 55.9±2.4 78.1±4.2 22.2±3.4** Example 2 30 56.7±3.0 79.5±3.8 22.8±2.9** Example 3 30 57.2±2.9 80.1±3.8 22.9±3.4** Example 4 30 55.3±3.2 76.6±3.8 21.3±3.6** Example 5 30 56.8±3.2 71.5±4.1 14.7±3.5* Example 6 30 54.2±2.7 68.1±3.5 13.9±3.3* Comparative Example 1 30 57.4±2.6 69.4±3.4 12.0±2.7## Comparative Example 2 30 56.4±1.4 67.3±2.7 10.9±3.3## Comparative Example 3 30 58.2±3.3 69.4±4.3 11.2±3.1## Comparative Example 4 30 55.9±4.6 67.5±4.0 11.6±4.5## Comparative Example 5 30 56.3±1.5 63.7±3.8 7.4±2.9## Comparative Example 6 30 58.4±3.6 66.5±2.8 8.1±3.3## Comparative Example 7 30 56.7±2.4 63.9±3.6 7.2±2.9## Comparative Example 8 30 54.5±2.8 62.4±3.9 7.9±3.4##

[0107] Note: * indicates that the difference between the embodiment group and the control group is significant (P < 0.05), ** indicates that the difference is extremely significant (P < 0.01); # indicates that the difference between the comparative example group and the embodiment 3 group is significant (P < 0.05), ## indicates that the difference is extremely significant (P < 0.01).

[0108] Table 6 shows that after the subjects in Example 1-6 groups tried the lozenges for relieving visual fatigue provided by the present invention for 60 days, the average visual persistence was greatly improved, all greater than 10%, indicating that the lozenges of the present invention can improve the visual persistence of subjects with visual fatigue, and the therapeutic effect is significant. Compared with the control group, the improvement value of visual persistence in Example 1-6 is significantly improved, and the plant extract synergistic component provided by the present invention has a significant gain effect on the efficacy of the overall formula, and the plant extract synergistic component plays a key role in relieving visual fatigue; compared with Comparative Examples 1-8, the improvement rate of visual persistence in Example 3 is significantly better than that in Comparative Examples 1-8, indicating that the lack of any one of the components in the plant extract synergistic component provided by the present invention will have an adverse effect on the performance of the overall formula.

[0109] Conclusion: The above human food trial shows that the lozenges of the present invention have obvious therapeutic effects on visual fatigue and visual persistence of the subjects, and can achieve the effect of relieving visual fatigue.

[0110] Although the specific embodiments of the present invention are described above, it should be understood by those skilled in the art that this is only for illustration and the protection scope of the present invention is defined by the appended claims. Those skilled in the art may make various changes or modifications to these embodiments without departing from the principles and essence of the present invention, but these changes and modifications all fall within the protection scope of the present invention.

Claims

1. A composition for relieving visual fatigue, characterized in that: The composition is made of the following active ingredients by weight: 5-10 parts of plant extract synergistic components; Lutein 0.01-0.02 parts; Zinc gluconate 0.01-0.02 parts; The plant extract synergistic component consists of bilberry extract, chrysanthemum extract, peanut skin extract and mulberry extract; The mass ratio of the bilberry extract, the chrysanthemum extract, the peanut skin extract and the mulberry extract is (2.5-3.5): (1.2-1.7): (0.1-0.4): (1.8-2.6); The preparation method of the peanut skin extract comprises the following steps: S1, drying, crushing and sieving the peanut skins to obtain peanut skin powder; S2, extracting the peanut skin powder obtained in step S1 in a supercritical CO2 extraction kettle to obtain a peanut skin extract; In the step S1, the peanut skins are dried at 60° C. for 4 hours, and then crushed, and passed through a 120-mesh sieve to obtain peanut skin powder; The supercritical CO2 extraction conditions in step S2 are: using 75 v / v% ethanol as the entrainer, the mass volume ratio of peanut skin powder to the entrainer is 1:2 g / mL, the entrainer flow acceleration is 0.5 L / h, the extraction temperature is 40°C, the extraction pressure is 10 MPa, the CO2 flow rate is 20 L / h, the separation pressure is 4 MPa, the separation temperature is 30°C, and the extraction time is 2 h.

2. The composition for relieving visual fatigue according to claim 1, characterized in that: The composition also includes excipients acceptable to functional foods or medicines.

3. Use of the composition for relieving visual fatigue according to claim 1 or 2 in the preparation of functional food with the effect of relieving visual fatigue.

4. A lozenge for relieving visual fatigue, characterized in that: The lozenge is composed of the composition for relieving visual fatigue according to claim 1 or 2, maltodextrin, magnesium stearate, silicon dioxide, microcrystalline cellulose and a flavoring agent.

5. The lozenge for relieving visual fatigue according to claim 4, characterized in that: The lozenge comprises the following components by mass percentage: Plant extract synergistic components 5-10%; Lutein 0.01-0.02%; Zinc gluconate 0.01-0.02%; Magnesium stearate 0.5-1%; Silicon dioxide 0.1-0.2%; Microcrystalline cellulose 15-20%; Flavoring agent 0.001-0.002%; Maltodextrin is added to 100%.

6. The method for preparing the buccal tablet for relieving visual fatigue according to claim 5, characterized in that: The method comprises the following preparation steps: A1. Mix the components of the plant extract synergistic component according to the mass ratio, and then perform ultrafine grinding for 30 minutes, and pass through a 120-mesh sieve to obtain ultrafine powder of the plant extract synergistic component; A2, maltodextrin and microcrystalline cellulose were subjected to ultrafine grinding for 30 min, and then maltodextrin was passed through a 120-mesh sieve and microcrystalline cellulose was passed through a 200-mesh sieve to obtain ultrafine maltodextrin powder and ultrafine microcrystalline cellulose powder; A3. Mix lutein, zinc gluconate and silicon dioxide to obtain mixed powder A, mix the superfine powder of plant extract synergistic component and the superfine powder of maltodextrin evenly, add superfine powder of microcrystalline cellulose to mix to obtain mixed powder B, then place the mixed powder A, mixed powder B, magnesium stearate and flavoring agent in a mixing device and mix for 15-30 minutes to obtain a total mixed powder, and finally tablet the total mixed powder to obtain the lozenge for relieving visual fatigue.

Images